Literature DB >> 1689899

Pharmacokinetics of FK 506: preclinical and clinical studies.

R Venkataramanan1, A Jain, E Cadoff, V Warty, K Iwasaki, K Nagase, A Krajack, O Imventarza, S Todo, J J Fung.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1689899      PMCID： PMC2903896     

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  1 in total

1.  In Vitro Immunosuppressive Effects of FK506 in Combination With Other Drugs.

Authors:  A Zeevi; R Duquesnoy; G Eiras; H Rabinowich; S Todo; L Makowka; T E Starzl
Journal:  Transplant Proc       Date:  1988-02-01       Impact factor: 1.066
  1 in total
  39 in total

1.  Effect of renal ischemia on plasma levels of FK 506 in rats.

Authors:  M Sakr; G Zetti; J Gavaler; H Farghali; R Venkataramanan; G Carrieri; T Starzl; D Van Thiel
Journal:  Transplant Proc       Date:  1992-02       Impact factor: 1.066

Review 2.  FK 506 and autoimmune disease: perspective and prospects.

Authors:  A W Thomson; T E Starzl
Journal:  Autoimmunity       Date:  1992       Impact factor: 2.815

3.  Strategy of FK 506 therapy in liver transplant patients: effect of graft function.

Authors:  K M Abu-Elmagd; J J Fung; M Alessiani; A Jain; S Takaya; R Venkataramanan; V S Warty; W Shannon; S Todo; A Tzakis
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

4.  Pharmacokinetics of FK 506 in transplant patients.

Authors:  R Venkataramanan; A Jain; V S Warty; K Abu-Elmagd; M Alessiani; J Lever; A Krajak; J Flowers; S Mehta; S Zuckerman
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

Review 5.  Adverse effects associated with the use of FK 506.

Authors:  J J Fung; M Alessiani; K Abu-Elmagd; S Todo; R Shapiro; A Tzakis; D Van Thiel; J Armitage; A Jain; J McCauley
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

6.  Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation.

Authors:  K M Abu-Elmagd; J Fung; R Draviam; W Shannon; A Jain; M Alessiani; S Takaya; R Venkataramanan; V S Warty; A Tzakis
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

7.  FK 506-associated diabetes mellitus in the pediatric transplant population is a rare complication.

Authors:  P B Carroll; H Rilo; J Reyes; R Alejandro; Y Zeng; C Ricordi; A Tzakis; R Shapiro; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

8.  Correlation between bioassayed plasma levels of FK 506 and lymphocyte growth from liver transplant biopsies with histological evidence of rejection.

Authors:  A Zeevi; G Eiras; C Kaufman; M Alessiani; A J Demetris; K Abu-Elmagd; A Jain; V Warty; R Venkataramanan; G Burckart
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

9.  Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine.

Authors:  R Venkataramanan; A Jain; V W Warty; K Abu-Elmagd; H Furakawa; O Imventarza; J Fung; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

10.  Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil.

Authors:  H Li; D E Mager; B M Sandmaier; D G Maloney; M J Bemer; J S McCune
Journal:  J Clin Pharmacol       Date:  2013-02-04       Impact factor: 3.126
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.